| A | B | C | D | E | |
|---|---|---|---|---|---|
| 1 | Main | ||||
| 2 | Brand | Lenvima | |||
| 3 | Generic | lenvatinib | |||
| 4 | Indication | differentiated thyroid cancer first indication | |||
| 5 | MOA | VEGFR1/2/3 inhibitor | |||
| 6 | Approval | 2/13/2015 | |||
| 7 | IP | 7253286 - 2025 first expiry | |||
| 8 | |||||
| 9 | 286 claim | ||||
| 10 | |||||
| 11 | |||||
| 12 | |||||
| 13 | 7612208 - 2026 expiry of crystal patent |